The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,392 | -3,935 |
| Depreciation and amortization | 2 | 0 |
| Amortization of right of use asset | 0 | 0 |
| Net gain/loss on disposal of property and equipment | 0 | 0 |
| Stock-based compensation | 113 | 94 |
| Prepaid expenses and other assets | 269 | 165 |
| Accounts payable | 281 | -18 |
| Accrued expenses | 180 | 209 |
| Lease liability | 0 | 0 |
| Net cash used in operating activities | -2,085 | -3,815 |
| Cash paid for purchase of property and equipment | 7 | 5 |
| Net cash used in investing activities | -7 | -5 |
| Net proceeds from the exercise of warrants | 200 | 2,720 |
| Net proceeds from the issuance of common stock and warrants | 8,345 | 6,493 |
| Payments of taxes for net shares settled restricted stock unit issuances | 30 | 0 |
| Net cash provided by financing activities | 2,022 | 9,213 |
| Net decrease in cash, cash equivalents and restricted cash | 5,323 | - |
| Cash and cash equivalents at beginning of period | 5,382 | - |
| Net increase (decrease) in cash and cash equivalents | - | 5,393 |
| Cash and cash equivalents at end of period | 10,705 | - |
Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp. (PHIO)